Table 1.
Patients’ general characteristics n (%)
| Numbers | |
| Age (range), yr | 531 (36-71) |
| Sex | |
| Male | 25 (81) |
| Female | 6 (19) |
| Etiology | |
| HBV | 26 (83.9) |
| HCV | 1 (3.2) |
| Others | 4 (12.9) |
| Status of primary liver mass | |
| Stable | 13 (41.9) |
| Progressive | 18 (58.1) |
| Metastatic sites | |
| Lung | 28 (90.3) |
| Lymph node | 10 (32.3) |
| Bone | 8 (25.1) |
| Peritoneum | 3 (9.7) |
| Previous treatment before sorafenib | |
| TACE | 29 (93.5) |
| Surgery | 17 (54.8) |
| Radiation | 12 (38.7) |
| Hepatic arterial infusion | 9 (29.0) |
| Radiofrequency ablation | 5 (16.1) |
1
Median. TACE: Transarterial chemoembolization; HBV: Hepatitis B virus; HCV: Hepatitis C virus.